Provectus Biopha Financials
This page shows Provectus Biopha (PVCT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Provectus Biopha passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Provectus Biopha generates $0.61 in operating cash flow (-$3.3M OCF vs -$5.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Provectus Biopha earns $-89.1 in operating income for every $1 of interest expense (-$5.3M vs $59K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Provectus Biopha generated $336K in revenue in fiscal year 2025. This represents a decrease of 45.5% from the prior year.
Provectus Biopha's EBITDA was -$5.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 17.0% from the prior year.
Provectus Biopha reported -$5.4M in net income in fiscal year 2025. This represents a decrease of 14.8% from the prior year.
Provectus Biopha earned $-0.01 per diluted share (EPS) in fiscal year 2025. This represents an increase of 0.0% from the prior year.
Cash & Balance Sheet
Provectus Biopha held $251K in cash against $0 in long-term debt as of fiscal year 2025.
Provectus Biopha had 420M shares outstanding in fiscal year 2025. This represents an increase of 0.0% from the prior year.
Margins & Returns
Provectus Biopha's operating margin was -1575.3% in fiscal year 2025, reflecting core business profitability. This is down 840.9 percentage points from the prior year.
Provectus Biopha's net profit margin was -1615.8% in fiscal year 2025, showing the share of revenue converted to profit. This is down 849.0 percentage points from the prior year.
Capital Allocation
Provectus Biopha invested $1.9M in research and development in fiscal year 2025. This represents a decrease of 5.1% from the prior year.
PVCT Income Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $57K-79.4% | $279K+1844.1% | $14K-86.9% | $110K-57.0% | $255K+7.1% | $238K+96.6% | $121K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $346K-60.1% | $867K+123.1% | $389K-30.2% | $557K+34.5% | $414K-12.5% | $473K-14.9% | $556K+33.6% | $416K |
| SG&A Expenses | $930K-6.2% | $991K+0.3% | $988K-44.9% | $1.8M+175.1% | $651K+12.9% | $577K+344.5% | $130K-58.1% | $310K |
| Operating Income | -$1.3M+29.2% | -$1.8M-64.0% | -$1.1M+53.0% | -$2.3M-144.3% | -$956K-20.2% | -$795K-77.7% | -$447K+26.0% | -$605K |
| Interest Expense | -$48K+6.5% | -$51K+19.3% | -$64K-133.4% | $190K+424.4% | -$59K+4.3% | -$61K-8.0% | -$57K-134.8% | $163K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$1.3M+27.7% | -$1.8M-59.1% | -$1.1M+51.8% | -$2.4M-133.4% | -$1.0M-19.8% | -$847K-68.0% | -$504K+24.0% | -$663K |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | N/A | $0.00 | $0.00 | $0.00 | N/A |
PVCT Balance Sheet
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $420K-41.9% | $722K+8.4% | $666K-33.8% | $1.0M+25.5% | $802K-6.4% | $856K-20.6% | $1.1M-25.5% | $1.4M |
| Current Assets | $278K-51.1% | $568K-12.5% | $649K-33.5% | $977K+28.5% | $760K-5.0% | $800K-20.7% | $1.0M-26.1% | $1.4M |
| Cash & Equivalents | $72K-81.2% | $386K-1.2% | $390K+27.0% | $307K+64.0% | $187K+533.7% | $30K+64.0% | $18K-76.4% | $77K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $6.6M-0.2% | $6.6M+15.0% | $5.7M-17.8% | $7.0M+12.1% | $6.2M-25.6% | $8.4M-1.9% | $8.5M-5.7% | $9.0M |
| Current Liabilities | $6.5M-0.3% | $6.5M+13.2% | $5.7M-17.8% | $7.0M+12.1% | $6.2M-25.6% | $8.4M-1.7% | $8.5M-5.6% | $9.0M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$6.2M-4.8% | -$5.9M-15.1% | -$5.1M+14.4% | -$6.0M-9.9% | -$5.4M+27.8% | -$7.5M-0.9% | -$7.4M+1.9% | -$7.6M |
| Retained Earnings | -$261.7M-0.5% | -$260.4M-0.7% | -$258.6M-0.4% | -$257.4M-0.9% | -$255.1M-0.4% | -$254.0M-0.3% | -$253.2M-0.2% | -$252.7M |
PVCT Cash Flow Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$840K-60.5% | -$523K+52.2% | -$1.1M-19.9% | -$912K-61.4% | -$565K+25.9% | -$763K+27.0% | -$1.0M-86.1% | -$561K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $496K+5.6% | $470K-56.2% | $1.1M+36.1% | $788K+33.8% | $589K+0.1% | $589K-24.6% | $781K+287.5% | $202K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
PVCT Financial Ratios
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | -3132.8%-2738.7pp | -394.1%+15894.9pp | -16289.0%-15418.1pp | -870.9%-559.1pp | -311.7%-123.8pp | -187.9%+311.4pp | -499.3% |
| Net Margin | N/A | -3156.6%-2747.4pp | -409.2%+16108.5pp | -16517.7%-15593.4pp | -924.3%-592.2pp | -332.1%-120.4pp | -211.7%+336.1pp | -547.8% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -312.3%-61.1pp | -251.2%-80.0pp | -171.1%+64.1pp | -235.3%-108.8pp | -126.5%-27.6pp | -98.9%-52.2pp | -46.7%-0.9pp | -45.8% |
| Current Ratio | 0.04-0.0 | 0.09-0.0 | 0.11-0.0 | 0.14+0.0 | 0.12+0.0 | 0.10-0.0 | 0.12-0.0 | 0.15 |
| Debt-to-Equity | -1.07+0.1 | -1.120.0 | -1.12+0.0 | -1.17-0.0 | -1.15-0.0 | -1.11+0.0 | -1.14+0.0 | -1.19 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$6.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.08), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Provectus Biopha's annual revenue?
Provectus Biopha (PVCT) reported $336K in total revenue for fiscal year 2025. This represents a -45.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Provectus Biopha's revenue growing?
Provectus Biopha (PVCT) revenue declined by 45.5% year-over-year, from $617K to $336K in fiscal year 2025.
Is Provectus Biopha profitable?
No, Provectus Biopha (PVCT) reported a net income of -$5.4M in fiscal year 2025, with a net profit margin of -1615.8%.
What is Provectus Biopha's EBITDA?
Provectus Biopha (PVCT) had EBITDA of -$5.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Provectus Biopha's operating margin?
Provectus Biopha (PVCT) had an operating margin of -1575.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Provectus Biopha's net profit margin?
Provectus Biopha (PVCT) had a net profit margin of -1615.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Provectus Biopha's operating cash flow?
Provectus Biopha (PVCT) generated -$3.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Provectus Biopha's total assets?
Provectus Biopha (PVCT) had $698K in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Provectus Biopha spend on research and development?
Provectus Biopha (PVCT) invested $1.9M in research and development during fiscal year 2025.
What is Provectus Biopha's current ratio?
Provectus Biopha (PVCT) had a current ratio of 0.08 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Provectus Biopha's debt-to-equity ratio?
Provectus Biopha (PVCT) had a debt-to-equity ratio of -1.11 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Provectus Biopha's return on assets (ROA)?
Provectus Biopha (PVCT) had a return on assets of -778.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Provectus Biopha's cash runway?
Based on fiscal year 2025 data, Provectus Biopha (PVCT) had $251K in cash against an annual operating cash burn of $3.3M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Provectus Biopha's debt-to-equity ratio negative or unusual?
Provectus Biopha (PVCT) has negative shareholder equity of -$6.3M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Provectus Biopha's Piotroski F-Score?
Provectus Biopha (PVCT) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Provectus Biopha's earnings high quality?
Provectus Biopha (PVCT) has an earnings quality ratio of 0.61x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Provectus Biopha cover its interest payments?
Provectus Biopha (PVCT) has an interest coverage ratio of -89.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.